Compare Charles River Laboratories Intl. Inc (CRL) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ServiceNow Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while ServiceNow Inc trades at $104.87 (market cap $108.13B). The key difference: ServiceNow Inc is far larger — about 9.7× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| CRL | NOW | |
|---|---|---|
Market Cap | $11.14B | $108.13B |
Sector | Health | Technology |
52-Week High | $233.60 | $199.24 |
52-Week Low | $145.57 | $83.00 |
Enterprise Value | $14.00B | $105.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
ServiceNow (NOW) trades at $111.26, up 3.3% on the day, with a bullish technical signal and strong fundamental growth. Revenue grew to $13.28B in 2025, with net income of $1.75B, though valuation ratios like P/E of 62.41 are elevated. Recent news highlights AI-driven growth opportunities, with the stock gaining 41% in May 2026 (Fool, 2026-06-03).
The outlook remains positive with an 85.51% analyst buy rating and a $137.41 consensus price target, implying significant upside. Risks include high valuation sensitivity and competitive pressures in enterprise AI. Cash flow trends show operational strength, but 2026 projections indicate potential net outflow, warranting monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
